⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681090 | 0.75 | — | — | |
| SCHEMBL13651594 | 0.75 | — | — | |
| SCHEMBL28620840 | 0.70 | — | — | |
| SCHEMBL6268947 | 0.66 | HSP90AA1 (0.34) | — | |
| SCHEMBL9468057 | 0.66 | HSP90AA1 (0.34) | — | |
| SCHEMBL15835939 | 0.66 | HSP90AA1 (0.34) | — | |
| SCHEMBL130426 | 0.65 | — | — | |
| SCHEMBL2011153 | 0.65 | — | — | |
| SCHEMBL28565567 | 0.65 | — | — | |
| SCHEMBL145778 | 0.65 | MAOA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335522-A | Compounds and methods for reducing APOE expression | 施能康公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115279904-A | Compositions and methods for inhibiting expression of the ASAH1 gene | 施能康公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-106661580-B | Antisense oligonucleotides for treating pompe disease | 鹿特丹伊拉斯谟大学医疗中心 | 2022-02-15 | — | — | CN | disclosed |
| CN-113430196-A | Compositions and methods for inhibiting gene expression of hepatitis b virus | 箭头药业股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-106434665-B | Compositions and methods for inhibiting gene expression of hepatitis b virus | 箭头药业股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-108273478-B | Formaldehyde removal composition and product | 李怀玉 | 2021-03-02 | — | — | CN | disclosed |
| US-20120040966-A1 | ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY | SOUTHERN RESEARCH INSTITUTE OFFICE OF COMMERCIALIZATION AND INTELLECTUAL PROP (US) | 2012-02-16 | — | — | US | disclosed |
| CN-101743326-A | Method for screening for single nucleotide variations in nucleic acids | INSIGHT GENETICS INC | 2010-06-16 | — | — | CN | disclosed |
| US-20090169472-A1 | METHODS AND COMPOSITIONS FOR TREATING IMMUNE DISORDERS | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2009-07-02 | — | — | US | disclosed |
| CN-101331230-A | Methods and compositions for treating immune disorders | CANCER REC TECH LTD (GB) | 2008-12-24 | — | — | CN | disclosed |
| EP-1937812-A2 | METHODS AND COMPOSITIONS FOR TREATING IMMUNE DISORDERS | Cancer Research Technology Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042554-A2 | METHODS AND COMPOSITIONS FOR TREATING IMMUNE DISORDERS | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2007-04-19 | — | — | WO | disclosed |
| CN-1514842-A | Processes of purifying oligonucleotides | ISISҩ�﹫˾ | 2004-07-21 | — | — | CN | disclosed |
| US-6509460-B1 | Contacting the modified nucleotide triphosphate with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |